Delivery Order SPE2DR25D9979-SPE2DR26FGWT6
- Not listed
- This is a $1,750.90 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award is for the delivery of Imitrex 6 mg/0.5 ml pen injectors, with a completion date of July 18, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency's (DLA) Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $1,312.12, is for the delivery of Imitrex 6 mg/0.5 ml pen injections to support the recurring medical supply needs of military health facilities. The award is part of DMS Pharmaceutical Group's broader indefinite delivery...
- The Defense Logistics Agency's Medical Supply Chain division awarded a $1,026.81 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Sumatriptan Succinate. This delivery order, issued on December 16, 2025, represents a single transaction under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the DLA. The award carries no set-aside designation,...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $1,711.35, is for the provision of Imitrex 6 mg/0.5 ml pen injectors to support the recurring medical supply needs of military healthcare facilities. The contract is not associated with any set-aside designation. DMS Pharmaceutical Group holds a significant single-award Indefinite...
- The Defense Logistics Agency Medical Supply Chain issued a firm fixed-price delivery order valued at $1,369.20 to DMS Pharmaceutical Group Inc. for Sumatriptan Succinate, a migraine treatment medication. The award was issued on December 5, 2025, with an ultimate completion date of the same day, reflecting a routine pharmaceutical supply transaction to support Department of Defense medical operations. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $4,588.96, is for the supply of IMITREX 6 MG/0.5 ML PEN INJECT 0.5ML, a prescription medication. The contract is a firm fixed-price delivery order with no set-aside designation. It is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program,...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on September 17, 2025, for the supply of Sumatriptan Succinate. This firm fixed-price delivery order, valued at $1,832.74, is set to be completed by September 18, 2025, with performance at the contractor's Park Ridge, Illinois location. The award carries no set-aside designation, allowing DMS Pharmaceutical...
- The U.S. Defense Logistics Agency's Medical Supply Chain division awarded a firm fixed-price delivery order valued at $1,711.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Sumatriptan Succinate. This delivery order was issued without a set-aside designation on December 10, 2025, with an ultimate completion date of the same date. DMS Pharmaceutical Group serves as a critical supplier within the federal...
- The U.S. Defense Logistics Agency (DLA), operating under the Medical Supply Chain division, awarded a firm fixed-price delivery order valued at $1,711.35 to DMS Pharmaceutical Group Inc. for the supply of Sumatriptan Succinate. The contract was awarded on July 14, 2025, with an ultimate completion date of July 24, 2025, and will be performed at the contractor's facility in Park Ridge, Illinois. No set-aside designation was utilized for this award. DMS Pharmaceutical Group Inc., a woman-owned...
- This federal contract award was issued by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,458.54 firm fixed-price delivery order is for the supply of Sumatriptan Succinate, a specialized pharmaceutical product, with a performance period through November 15, 2024. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the...
- SPE2DR25D9979Indefinite Delivery Contract
- SPE2DR25D9979-SPE2DR26FGWT6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,778.15 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Imitrex 6 mg/0.5 ml pen injections. This firm fixed-price delivery order, issued on December 22, 2025, with an ultimate completion date of December 23, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. serves as the prime contractor with no identified subcontractors on this award. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The parent IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors within the broader $30.3 billion PPV-G GEN V acquisition strategy. This framework enables the DLA to issue delivery orders for pharmaceutical products and medical consumables to support the recurring medical supply needs of military healthcare facilities worldwide, with DMS Pharmaceutical Group's established performance on numerous delivery orders demonstrating its capability to fulfill the diverse pharmaceutical requirements of the Department of Defense healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 12/21/25 |